<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31907874</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Repeat Expansion Disorders: Mechanisms and Therapeutics.</ArticleTitle><Pagination><StartPage>924</StartPage><EndPage>927</EndPage><MedlinePgn>924-927</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00823-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellerby</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-9050-7977</Identifier><AffiliationInfo><Affiliation>Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, CA, 94945, USA. lellerby@buckinstitute.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS100529</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS100529</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005621" MajorTopicYN="N">Friedreich Ataxia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31907874</ArticleId><ArticleId IdType="pmc">PMC6985307</ArticleId><ArticleId IdType="doi">10.1007/s13311-019-00823-3</ArticleId><ArticleId IdType="pii">10.1007/s13311-019-00823-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, et al. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem. 1999;274(13):8730&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10085113</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellerby LM, Hackam AS, Propp SS, Ellerby HM, Rabizadeh S, Cashman NR, et al. Kennedy&#x2019;s disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem. 1999;72(1):185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9886069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem. 2004;279(19):20211&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14981075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafni J, Papanikolaou T, Degiacomo F, Holcomb J, Chen S, Menalled L, et al. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci. 2012;32(22):7454&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454486</ArticleId><ArticleId IdType="pubmed">22649225</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFevre-Bernt MA, Ellerby LM. Kennedy&#x2019;s disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem. 2003;278(37):34918&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12824190</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyva MJ, Degiacomo F, Kaltenbach LS, Holcomb J, Zhang N, Gafni J, et al. Identification and evaluation of small molecule pan-caspase inhibitors in Huntington&#x2019;s disease models. Chem Biol. 2010;17(11):1189&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3035168</ArticleId><ArticleId IdType="pubmed">21095569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington&#x2019;s disease. J Neurosci. 2002;22(18):7862&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758089</ArticleId><ArticleId IdType="pubmed">12223539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998;273(15):9158&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9535906</ArticleId></ArticleIdList></Reference><Reference><Citation>Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 2000;275(26):19831&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10770929</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ. Merry DE. Neurotherapeutics: Molecular Mechanisms and Therapeutics for SBMA/Kennedy&#x2019;s Disease; 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId></ArticleIdList></Reference><Reference><Citation>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. The Huntington&#x2019;s Disease Collaborative Research Group. Cell. 1993;72(6):971&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiuri T, Suart CE, Hung CLK, Graham KJ, Barba Bazan CA, Truant R. DNA Damage Repair in Huntington&#x2019;s Disease and Other Neurodegenerative Diseases. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985310</ArticleId><ArticleId IdType="pubmed">31364066</ArticleId></ArticleIdList></Reference><Reference><Citation>Creus-Muncunill J, Ehrlich ME. Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington&#x2019;s Disease: Insights from In Vitro and In Vivo Models. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985401</ArticleId><ArticleId IdType="pubmed">31529216</ArticleId></ArticleIdList></Reference><Reference><Citation>Naphade S, Tshilenge KT, Ellerby LM. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985408</ArticleId><ArticleId IdType="pubmed">31792895</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Jr, Servadio A, Beaudet AL, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4(3):221&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8358429</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan SR, Shakkottai VG. Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985354</ArticleId><ArticleId IdType="pubmed">31338702</ArticleId></ArticleIdList></Reference><Reference><Citation>Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet. 1993;4(3):300&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8358439</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Silva JD, Teixeira-Castro A, Maciel P. From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985322</ArticleId><ArticleId IdType="pubmed">31691128</ArticleId></ArticleIdList></Reference><Reference><Citation>Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich&#x2019;s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8596916</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesfeld JM. Molecular Mechanisms and Therapeutics for the GAA.TTC Expansion Disease Friedreich Ataxia. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985418</ArticleId><ArticleId IdType="pubmed">31317428</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996;14(3):285&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14(3):269&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique. DIRECT. Nat Genet. 1996;14(3):277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896556</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova PA, Bezprozvanny IB. Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985344</ArticleId><ArticleId IdType="pubmed">31435879</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewiadomska-Cimicka A, Trottier Y. Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985300</ArticleId><ArticleId IdType="pubmed">31432449</ArticleId></ArticleIdList></Reference><Reference><Citation>Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, Saito M, et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet. 1999;8(11):2047&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10484774</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Pan Y, Li XJ, Li S. Molecular Mechanisms and Therapeutics for SCA17. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985407</ArticleId><ArticleId IdType="pubmed">31317427</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato N, Amino T, Kobayashi K, Asakawa S, Ishiguro T, Tsunemi T, et al. Spinocerebellar ataxia type 31 is associated with &#x201c;inserted&#x201d; penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet. 2009;85(5):544&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2775824</ArticleId><ArticleId IdType="pubmed">19878914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa K, Nagai Y. Molecular Mechanisms and Future Therapeutics for Spinocerebellar Ataxia Type 31 (SCA31). Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985187</ArticleId><ArticleId IdType="pubmed">31755042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Ravits J. Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia. Neurotherapeutics. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985338</ArticleId><ArticleId IdType="pubmed">31667754</ArticleId></ArticleIdList></Reference><Reference><Citation>Bragg DC, Sharma N, Ozelius LJ. X-Linked Dystonia-Parkinsonism: recent advances. Curr Opin Neurol. 2019;32(4):604&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243267</ArticleId><ArticleId IdType="pubmed">31116117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>